科伦博泰生物-B宣布,其靶向Trop2的抗体偶联药物(ADC)Sacituzumab Tirumotecan已获得国家药品监督管理局(NMPA)批准上市。这是该药物获批的第四项适应症,标志着其在临床应用范围的进一步扩大。
科伦博泰生物-B宣布,其靶向Trop2的抗体偶联药物(ADC)Sacituzumab Tirumotecan已获得国家药品监督管理局(NMPA)批准上市。这是该药物获批的第四项适应症,标志着其在临床应用范围的进一步扩大。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.